ZFIN ID: ZDB-PUB-170808-2
Teratogenic Effects of Topiramate in a Zebrafish Model
Lai, Y.H., Ding, Y.J., Moses, D., Chen, Y.H.
Date: 2017
Source: International Journal of Molecular Sciences   18(8): 1721 (Journal)
Registered Authors: Chen, Yau-Hung, Ding, Yu-Ju
Keywords: ceratobranchial defect, teratology, topiramate, zebrafish
MeSH Terms:
  • Animals
  • Body Weight/drug effects
  • Chondrogenesis/drug effects
  • Craniofacial Abnormalities/chemically induced
  • Female
  • Fructose/analogs & derivatives*
  • Fructose/pharmacology
  • Fructose/toxicity
  • Models, Animal
  • Oocytes/drug effects
  • Oocytes/pathology
  • Oogenesis/drug effects
  • Teratogenesis/drug effects*
  • Teratogens/pharmacology*
  • Teratogens/toxicity
  • Zebrafish
PubMed: 28783116 Full text @ Int. J. Mol. Sci.
Topiramate is commonly used for treating epilepsy in both children and adults. Recent clinical data suggests that administration of topiramate to women during pregnancy increases the risk of oral clefts in their offspring. To better understand the potential effects of topiramate, we dosed adult female zebrafish with topiramate, and investigated the altered morphologies in adult females and their offspring. It showed that topiramate-treated female fish had reduced oocyte maturation, and the survival rates of their offspring were seriously decreased during embryogenesis. In addition, around 23% of offspring displayed cartilage malformation in the craniofacial area, such as loss of ceratobranchial cartilages as well as impaired ceratohyal, Meckel's cartilage and ethmoid plate development. Moreover, mineralization of ceratohyal, Meckel's cartilage, and vertebrae were downregulated during bone development. Taken together, we concluded that topiramate impaired oogenesis in the maternal reproductive system, and then caused offspring cartilage malformation or bone dysplasia.